BiotechTube

Sparsentan + Sparsentan + Sparsentan

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Segmental Glomerulosclerosis

Conditions

Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome

Trial Timeline

Aug 12, 2021 → Apr 12, 2027

NCT ID
NCT05003986

About Sparsentan + Sparsentan + Sparsentan

Sparsentan + Sparsentan + Sparsentan is a phase 2 stage product being developed by Travere Therapeutics for Focal Segmental Glomerulosclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05003986. Target conditions include Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy.

What happened to similar drugs?

4 of 10 similar drugs in Focal Segmental Glomerulosclerosis were approved

Approved (4) Terminated (1) Active (6)
✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
✅DapagliflozinAstraZenecaApproved
✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved
🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3
🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05003986Phase 2Recruiting

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
35
DapagliflozinAstraZenecaApproved
43
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
35
CCX140-BAmgenPhase 2
27
PF-06730512PfizerPhase 2
27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
43
VX-147Vertex PharmaceuticalsPhase 2
35
VX-147Vertex PharmaceuticalsPhase 1
29
IXPVertex PharmaceuticalsPhase 1
29
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
35
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
29
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
42
VivaglobinCSLPhase 2
35
UCB0942UCBPhase 2
27
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
43
Brivaracetam + BrivaracetamUCBPhase 2
35
LacosamideUCBPhase 2
27
UCB0942 + UCB0942 + PlaceboUCBPhase 2
35
LacosamideUCBPre-clinical
26
ARGX-117ArgenxPhase 2
36